Search by Drug Name or NDC
NDC 68727-0712-01 ZEPZELCA 0.5 mg/mL Details
ZEPZELCA 0.5 mg/mL
ZEPZELCA is a INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Jazz Pharmaceuticals, Inc.. The primary component is LURBINECTEDIN.
MedlinePlus Drug Summary
Lurbinectedin injection is used to treat small cell lung cancer (SCLC) that has spread to other parts of the body and did not improve during or after treatment with platinum chemotherapy. Lurbinectedin injection is in a class of medications called alkylating agents. It works by slowing or stopping the growth of cancer cells in your body.
Related Packages: 68727-0712-01Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Lurbinectedin Injection
Product Information
NDC | 68727-0712 |
---|---|
Product ID | 68727-712_3d667d47-35e9-4eeb-a5a6-2a879f52eac5 |
Associated GPIs | 21100024002120 |
GCN Sequence Number | 081197 |
GCN Sequence Number Description | lurbinectedin VIAL 4 MG INTRAVEN |
HIC3 | V1A |
HIC3 Description | ANTINEOPLASTIC - ALKYLATING AGENTS |
GCN | 48241 |
HICL Sequence Number | 046626 |
HICL Sequence Number Description | LURBINECTEDIN |
Brand/Generic | Brand |
Proprietary Name | ZEPZELCA |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | Lurbinectedin |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
Route | INTRAVENOUS |
Active Ingredient Strength | 0.5 |
Active Ingredient Units | mg/mL |
Substance Name | LURBINECTEDIN |
Labeler Name | Jazz Pharmaceuticals, Inc. |
Pharmaceutical Class | Alkylating Activity [MoA], Alkylating Drug [EPC] |
DEA Schedule | n/a |
Marketing Category | NDA |
Application Number | NDA213702 |
Listing Certified Through | 2024-12-31 |
Package
NDC 68727-0712-01 (68727071201)
NDC Package Code | 68727-712-01 |
---|---|
Billing NDC | 68727071201 |
Package | 8 mL in 1 VIAL, SINGLE-DOSE (68727-712-01) |
Marketing Start Date | 2020-06-15 |
NDC Exclude Flag | N |
Pricing Information | N/A |